Month: March 2026

How Long Should We Treat Pediatric Outpatient CAP? Rethinking Antibiotic Duration

Posted on by

By Nicole Pietraszewski PharmD Candidate,

Community acquired pneumonia (CAP) is the cause of about 1.5 million pediatric medical visits each year and remains the second-leading cause of pediatric hospitalizations in the United States.1 The 2011  Pediatric Infectious Disease Society and Infectious Diseases Society of America (PIDS/IDSA) guideline for pediatric CAP, currently archived, recommends a 10-day treatment course for most patients, as available evidence at the time supported that duration.2 Although the guideline acknowledged that shorter courses might be effective for uncomplicated outpatient cases and could help limit resistance, it has not been updated to reflect more recent data supporting shorter treatment durations.2

Importantly, the 2024 Report of the Committee on Infectious Diseases of the American Academy of Pediatrics (AAP Red Book)  currently recommends a 5-day treatment duration for uncomplicated CAP, while recognizing that longer courses remain appropriate for complicated infection.3 This guidance sets the stage for pharmacists to help standardize shorter, evidence-based CAP treatment durations across outpatient settings.

What do different guidelines recommend for pediatric outpatient CAP?

Other guidance has moved toward shorter (3-5 day) antibiotic courses for outpatient pediatric CAP.4,5 Both the World Health Organization (WHO) and the United Kingdom’s National Institute for Health and Care Excellence (NICE) published guidelines in 2024 and 2025, and respectively recommend this short duration.4,5

What evidence is there for short-duration treatment for pediatric outpatient CAP?

A large meta-analysis published compared short-duration treatment (3-5 days) versus long-duration treatment (5-10 days) antibiotic therapy in children (<18 years old) with CAP.1 The analysis included 16 randomized controlled trials, published from inception to April 30, 2022, with a total of 12,774 patients.1

Shorter antibiotic courses had similar outcomes as longer ones.1 There was no significant difference found in the odds of clinical cure (n=7,298; OR 1.01, 95% CI 0.87 to 1.17), risk of treatment failure which included generally worsening or non-improving illness requiring treatment change, hospitalization (n=10,303; RR 1.06, 95% CI 0.93 to 1.21), mortality (n=9,058; RD 0.0%, 95% CI -0.2 to 0.1), or adverse effects (n=2,249; RR 0.75, 95% CI 0.44 to 1.28).1 The subgroup analysis showed no differences by age, same or different drug class, and high or low income countries.1

A more focused CAP meta-analysis included all high-income country trials namely CAP-IT, SCOUT-CAP, SAFER, and the 2014 Greenberg trial.1,6 The meta-analysis, which is more applicable to US patients based on population and treatments, evaluated randomized controlled trials published from 2003 to 2022, concluded that 3-5 days was as safe and effective as 7-10 days in patients with uncomplicated CAP.6 It only included trials comparing beta-lactam therapies, consistent with PIDS/IDSA and AAP Red Book recommendations that amoxicillin is first-line for non-severe CAP.2,3,6

Populations of Focused CAP Meta-Analysis

This analysis found no difference between either treatment failure, defined as the need for antibiotic retreatment one month after initial course or hospitalization (n=1,541; RD -0.00, 95% CI -.03 to 0.02), or in adverse effects (n=1,194; RD -0.00, 95% CI -.05 to 0.05). 6

Overall, recent evidence supports 3 to 5 day beta-lactam treatment for children of at least 6 months old with uncomplicated CAP, primarily outpatient.

What does this mean for practice and what’s next?

Antimicrobial stewardship programs in the inpatient arena have demonstrated strong improvements in antimicrobial prescribing.  This strong evidence, specific to pediatric CAP, provides an opportunity for pharmacists in ambulatory settings (e.g., community, clinics, emergency departments) to improve review their current practice, and if warranted implement antimicrobial stewardship efforts to reduce routine prescribing to 3-5 day durations of amoxicillin for most pediatric outpatient CAP cases,

About the author: Nicole Pietraszewski, is a Doctor of Pharmacy candidate at the University of Connecticut. This post was written as part of her Advanced Pharmacy Practice Experience under the guidance of her professor, Jennifer Girotto PharmD, BCPPS, BCIDP, who also reviewed and edited the piece.

References

  1. Gao Y, Liu M, Yang K, et al. Shorter versus longer-term antibiotic treatments for community-acquired pneumonia in children: A meta-analysis. Pediatrics. 2023;151(6):e2022060097. doi: 10.1542/peds.2022–060097. doi: 10.1542/peds.2022-060097.
  2. Bradley JS, Byington CL, Shah SS, et al. Executive summary: The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of america. Clin Infect Dis. 2011;53(7):617–630. doi: 10.1093/cid/cir625.
  3. Systems-based treatment tableCommittee on Infectious Diseases, American Academy of Pediatrics, Kimberlin DW, Banerjee R, Barnett ED, Lynfield R, Sawyer MH, eds. Red book: 2024–2027 report of the committee on infectious diseases. American Academy of Pediatrics; 2024:0. https://doi.org/10.1542/9781610027373-TAB. Accessed 2/9/2026. 10.1542/9781610027373-TAB.
  4. World Health Organization. Guideline on management of pneumonia and diarrhoea in children up to 10 years of age. 2024. https://iris.who.int/server/api/core/bitstreams/bddcc725-8ffd-4d38-bec4-d6ead2904911/content.
  5. National Institute for Health and Care Excellence. Pneumonia: Diagnosis and
    management. 2025.
  6. Kuitunen I, Jääskeläinen J, Korppi M, Renko M. Antibiotic treatment duration for community-acquired pneumonia in outpatient children in high-income countries-A systematic review and meta-analysis. Clin Infect Dis. 2023;76(3):e1123–e1128. doi: 10.1093/cid/ciac374.
  7. Bielicki JA, Stöhr W, Barratt S, et al. Effect of amoxicillin dose and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia: The CAP-IT randomized clinical trial. JAMA. 2021;326(17):1713–1724. doi: 10.1001/jama.2021.17843.
  8. Williams DJ, Creech CB, Walter EB, et al. Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: The SCOUT-CAP randomized clinical trial. JAMA Pediatr. 2022;176(3):253–261. doi: 10.1001/jamapediatrics.2021.5547.
  9. Pernica JM, Harman S, Kam AJ, et al. Short-course antimicrobial therapy for pediatric community-acquired pneumonia: The SAFER randomized clinical trial. JAMA Pediatr. 2021;175(5):475–482. doi: 10.1001/jamapediatrics.2020.6735.
  10. Greenberg D, Givon-Lavi N, Sadaka Y, Ben-Shimol S, Bar-Ziv J, Dagan R. Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: A double-blind, randomized, placebo-controlled trial. Pediatr Infect Dis J. 2014;33(2):136–142. doi: 10.1097/INF.0000000000000023.